DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado
Hospital Universitario La Fe
Valencia, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario La Fe (14)
2023
-
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
Investigational New Drugs, Vol. 41, Núm. 5, pp. 677-687
2022
-
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34
-
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study
European Journal of Cancer, Vol. 172, pp. 340-348
2021
-
Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group
Clinical and Translational Oncology, Vol. 23, Núm. 1, pp. 58-64
2018
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
-
Radium-223 international early access program: Results from the Spanish subset
Future Oncology, Vol. 14, Núm. 1, pp. 41-50
2017
-
Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer
European Urology Focus, Vol. 3, Núm. 2-3, pp. 280-286
-
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Scientific Reports, Vol. 7
-
Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients
Journal of the National Cancer Institute, Vol. 109, Núm. 4
-
Translational research in neuroendocrine tumors: Pitfalls and opportunities
Oncogene, Vol. 36, Núm. 14, pp. 1899-1907
2015
2014
-
Prognostic factors for relapse in stage I seminoma: A new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)
Annals of Oncology, Vol. 25, Núm. 11, pp. 2173-2178
-
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma
Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 6, pp. 1095-1107